Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Parkinson's disease as a multi-axis systems disorder: integrating molecular pathology and circuit-level therapeutics.

Cell communication and signaling : CCS·2026

Same author

Extracellular Vesicles in Osteoarthritis: From Pathogenic Mediators to Engineered Therapeutics in a Precision Medicine Roadmap.

Journal of extracellular biology·2026

Same author

Prevalence of depression, anxiety and stress and associated workplace stressors among healthcare workers in a tertiary hospital in Vietnam: A cross-sectional study.

PloS one·2026

Same author

Cell Therapy for Spinal Cord Injury: Mechanistic Insights and Translational Challenges.

Cellular and molecular neurobiology·2026

Same author

Alzheimer's disease as a systems-level timing disorder: Circadian disruption of glial immunometabolism, brain clearance, and therapeutic responsiveness.

Neurobiology of sleep and circadian rhythms·2026

Same author

Immunometabolism Reframes Alzheimer's Disease: From Systemic Dysmetabolism to Glial Rewiring.

Cellular and molecular neurobiology·2026

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences.

Duc-Hiep Bach¹, Thanh Liem Nguyen¹

¹Vinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Hanoi, Vietnam.

Human Gene Therapy

|July 10, 2026

Summary

Manufacturing platforms significantly impact CAR T-cell therapy outcomes. Understanding integration biology, clonal fitness, and epigenomic imprinting is crucial for optimizing efficacy, safety, and accessibility of these advanced cancer treatments.

Keywords:

CAR-T manufacturing platforms clonal fitness epigenomic imprinting immune reconstitution nonviral gene delivery

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: Jul 12, 2026

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

Immunology
Biotechnology
Oncology

Background:

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematological cancer treatment.
Variability in CAR T-cell therapy outcomes is not fully explained by antigen choice or patient characteristics.

Purpose of the Study:

To propose manufacturing platforms as active biological determinants of CAR T-cell therapy outcomes.
To present a mechanistic framework for understanding how manufacturing influences therapy efficacy, durability, and safety.

Main Methods:

Review of viral and nonviral manufacturing strategies for CAR T-cell therapy.
Analysis of a three-layer mechanistic framework: integration biology, clonal fitness, and epigenomic imprinting.
Examination of clinical observations linking manufacturing platform choice to immune recovery and patient outcomes.

Main Results:

Viral vectors offer stable integration but face limitations in cost and capacity.
Nonviral strategies provide faster, cheaper manufacturing with larger payloads but distinct safety/persistence profiles.
Manufacturing platform choice impacts immune recovery, with implications for infection-related mortality and hematopoietic reserve.

Conclusions:

Manufacturing processes are integral to CAR T-cell therapy biology and clinical outcomes.
Decentralized, nonviral production holds potential for democratizing cell therapy and ensuring equitable access.
Optimizing manufacturing is key to transitioning CAR T-cell therapy from innovation to sustainable global care.